{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Androgen+Receptor+Pathway+Inhibitor+%28ARPI%29", "query": { "intervention": "Androgen Receptor Pathway Inhibitor (ARPI)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 19, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Androgen+Receptor+Pathway+Inhibitor+%28ARPI%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T13:05:59.243Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06894511", "title": "An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration Resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "AAA617", "type": "DRUG" }, { "name": "ARPI: Abiraterone", "type": "DRUG" }, { "name": "ARPI: Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 7, "start_date": "2025-09-11", "completion_date": "2026-10-15", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-09-29T13:05:59.243Z", "location_count": 5, "location_summary": "Casa Grande, Arizona • Gilbert, Arizona • Newport Beach, California + 2 more", "locations": [ { "city": "Casa Grande", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06894511" }, { "nct_id": "NCT05176483", "title": "Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma (RCC)", "Metastatic Castration-Resistant Prostate Cancer (mCRPC)", "Urothelial Carcinoma (UC)", "Solid Tumor", "Hepatocellular Carcinoma (HCC)", "Non-small Cell Lung Cancer (NSCLC)", "Colorectal Cancer (CRC)", "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Clear Cell Renal Cell Carcinoma (ccRCC)", "Non-Clear Cell Renal Cell Carcinoma (nccRCC)", "Drug-Drug Interaction (DDI)" ], "interventions": [ { "name": "Zanzalintinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab + Relatlimab", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "DDI Probe Cocktail", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1394, "start_date": "2021-12-14", "completion_date": "2030-06-28", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-09-29T13:05:59.243Z", "location_count": 46, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 38 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Littleton", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05176483" }, { "nct_id": "NCT07047118", "title": "A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Cancer, Castration-Resistant" ], "interventions": [ { "name": "JSB462", "type": "DRUG" }, { "name": "AAA617", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 138, "start_date": "2025-07-03", "completion_date": "2028-05-14", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-09-29T13:05:59.243Z", "location_count": 10, "location_summary": "Duarte, California • Santa Monica, California • Denver, Colorado + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07047118" }, { "nct_id": "NCT07216248", "title": "Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Hormone-sensitive Prostate Cancer (mHSPC)" ], "interventions": [ { "name": "relugolix + ARPI.", "type": "DRUG" }, { "name": "Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI", "type": "DRUG" }, { "name": "relugolix or androgen deprivation therapy (ADT) + ARPI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 160, "start_date": "2025-10-27", "completion_date": "2031-10", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-09-29T13:05:59.243Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07216248" }, { "nct_id": "NCT06855277", "title": "Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "AAA817", "type": "DRUG" }, { "name": "ARPI", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 940, "start_date": "2025-07-01", "completion_date": "2032-11-04", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-09-29T13:05:59.243Z", "location_count": 38, "location_summary": "Homewood, Alabama • Orange, California • Palo Alto, California + 33 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06855277" }, { "nct_id": "NCT07645326", "title": "RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Hormone-sensitive Prostate Cancer (mHSPC)" ], "interventions": [ { "name": "Androgen Deprivation Therapy (ADT)", "type": "DRUG" }, { "name": "Androgen Receptor Pathway Inhibitor (ARPI)", "type": "DRUG" }, { "name": "Prostate Radiation", "type": "RADIATION" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 108, "start_date": "2026-08", "completion_date": "2032-08", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-09-29T13:05:59.243Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07645326" }, { "nct_id": "NCT07677267", "title": "A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostatic Neoplasms, Castration-Resistant" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "115 Years", "sex": "MALE", "summary": "18 Years to 115 Years · Male only" }, "enrollment_count": 1067, "start_date": "2026-06-30", "completion_date": "2026-11-30", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-09-29T13:05:59.243Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07677267" }, { "nct_id": "NCT07226986", "title": "A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy" ], "interventions": [ { "name": "AMO959", "type": "DRUG" }, { "name": "AAA617", "type": "RADIATION" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 123, "start_date": "2025-12-05", "completion_date": "2029-09-13", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-09-29T13:05:59.243Z", "location_count": 3, "location_summary": "Los Angeles, California • El Paso, Texas • Murray, Utah", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "El Paso", "state": "Texas" }, { "city": "Murray", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07226986" }, { "nct_id": "NCT07103018", "title": "A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer", "Metastatic Castration-Resistant Prostate Cancer Patients", "Metastatic Castration-resistant Prostate Cancer, mCRPC", "mCRPC", "mCRPC (Metastatic Castration-resistant Prostate Cancer)" ], "interventions": [ { "name": "KTX-2001", "type": "DRUG" }, { "name": "KTX-2001 + Darolutamide (NUBEQA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "K36 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 144, "start_date": "2025-11-21", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-09-29T13:05:59.243Z", "location_count": 13, "location_summary": "San Francisco, California • Miami, Florida • Port Saint Lucie, Florida + 8 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07103018" }, { "nct_id": "NCT07570979", "title": "A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "INR731", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Androgen deprivation therapy (ADT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 208, "start_date": "2026-05-25", "completion_date": "2030-06-03", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-09-29T13:05:59.243Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Dallas, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07570979" } ] }